F.D.A. Advisers Endorse Paxlovid’s Benefits as a Covid Treatmentnews2023-03-16T21:15:49+00:00March 16th, 2023|The New York Times|
The Medicine Is a Miracle, but Only if You Can Afford Itnews2023-02-07T14:47:34+00:00February 7th, 2023|The New York Times|
Why Experts Are Urging Swifter Treatment for Children With Obesitynews2023-01-27T21:40:22+00:00January 27th, 2023|The New York Times|
Medicare Begins to Rein In Drug Costs for Older Americansnews2023-01-14T16:52:43+00:00January 14th, 2023|The New York Times|
FDA Approves, Leqembi, New Treatment for Early Alzheimer’snews2023-01-06T22:58:48+00:00January 6th, 2023|The New York Times|
Walmart Agrees to Pay $3.1 Billion to Settle Opioid Lawsuitsnews2022-11-15T19:30:25+00:00November 15th, 2022|The New York Times|
Medication Treatment for Addiction Is Shorter for Black and Hispanic Patients, Study Findsnews2022-11-09T17:28:16+00:00November 9th, 2022|The New York Times|
FDA Approves ALS Treatment Despite Questions About Effectivenessnews2022-09-29T21:14:36+00:00September 29th, 2022|The New York Times|
Monkeypox Appears to Recede, but Risks and Uncertainties Lingernews2022-09-26T09:00:17+00:00September 26th, 2022|The New York Times|
